Drugs / DTaP-IPV//PRP~T
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02094833 Comparator | Mar 2014 → Apr 2016 | diphtheria, haemophilus infectious disease, hepatitis B virus infection, pertussis +2 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTaP-IPV//PRP~T | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02094833 ↗ |
| Modality | Vaccine | “DTaP IPV//PRP~T combined vaccine (Pentaxim™)” NCT02094833 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular” NCT02094833 ↗ |